115 related articles for article (PubMed ID: 22455430)
1. Bevacizumab in ovarian cancer.
Mountzios G; Pentheroudakis G
N Engl J Med; 2012 Mar; 366(13):1257; author reply 1258. PubMed ID: 22455430
[No Abstract] [Full Text] [Related]
2. Bevacizumab in ovarian cancer.
Copur MS; Obermiller AM; Ramaekers R
N Engl J Med; 2012 Mar; 366(13):1256-7; author reply 1257-8. PubMed ID: 22455429
[No Abstract] [Full Text] [Related]
3. Bevacizumab in ovarian cancer.
Korn EL; Freidlin B; Abrams JS
N Engl J Med; 2012 Mar; 366(13):1256; author reply 1257-8. PubMed ID: 22455428
[No Abstract] [Full Text] [Related]
4. Angiogenesis inhibitors in the treatment of epithelial ovarian cancer.
Han ES; Wakabayashi M; Leong L
Curr Treat Options Oncol; 2013 Mar; 14(1):22-33. PubMed ID: 23288484
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab for the treatment of epithelial ovarian cancer: will this be its finest hour?
Kaye SB
J Clin Oncol; 2007 Nov; 25(33):5150-2. PubMed ID: 18024860
[No Abstract] [Full Text] [Related]
6. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
Teoh D; Secord AA
Int J Gynecol Cancer; 2012 Mar; 22(3):348-59. PubMed ID: 22266932
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic agents should be integrated into the standard treatment for patients with ovarian cancer.
Burger RA
Ann Oncol; 2011 Dec; 22 Suppl 8():viii65-viii68. PubMed ID: 22180405
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab in ovarian cancer: unanswered questions.
Muggia F
Drugs; 2012 May; 72(7):931-6. PubMed ID: 22564133
[No Abstract] [Full Text] [Related]
9. Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease.
Monk BJ; Pujade-Lauraine E; Burger RA
Ann Oncol; 2013 Dec; 24 Suppl 10():x53-x58. PubMed ID: 24265406
[TBL] [Abstract][Full Text] [Related]
10. Challenges to the paclitaxel/carboplatin algorithm in ovarian cancer treatment.
Zorn KK
Oncology (Williston Park); 2010 Jul; 24(8):738, 740. PubMed ID: 20718253
[No Abstract] [Full Text] [Related]
11. The use of bevacizumab in the management of ovarian cancer: an argument for single-agent rather than combination therapy.
Markman M
Ann Oncol; 2011 Dec; 22 Suppl 8():viii69-viii71. PubMed ID: 22180406
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab in treatment of high-risk ovarian cancer--a cost-effectiveness analysis.
Chan JK; Herzog TJ; Hu L; Monk BJ; Kiet T; Blansit K; Kapp DS; Yu X
Oncologist; 2014 May; 19(5):523-7. PubMed ID: 24721817
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab as front-line treatment for newly diagnosed epithelial cancer.
González Martín A; Bratos R; Márquez R; Alonso S; Chiva L
Expert Rev Anticancer Ther; 2013 Feb; 13(2):123-9. PubMed ID: 23406552
[TBL] [Abstract][Full Text] [Related]
14. First-line and maintenance therapy for ovarian cancer: current status and future directions.
González-Martín A; Sánchez-Lorenzo L; Bratos R; Márquez R; Chiva L
Drugs; 2014 Jun; 74(8):879-89. PubMed ID: 24848752
[TBL] [Abstract][Full Text] [Related]
15. The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer.
Gubbi A; Kendrick JE; Finkler NJ
Expert Rev Anticancer Ther; 2014 Oct; 14(10):1105-13. PubMed ID: 25189201
[TBL] [Abstract][Full Text] [Related]
16. Long-term remission in a patient with heavily pretreated, advanced ovarian cancer achieved by bevacizumab and metronomic cyclophosphamide treatment.
Aigner J; Bischofs E; Hallscheidt P; Sohn C; Schneeweiss A; Eichbaum M
Anticancer Drugs; 2011 Nov; 22(10):1030-3. PubMed ID: 21970854
[TBL] [Abstract][Full Text] [Related]
17. Prognostic importance of cell-free DNA in chemotherapy resistant ovarian cancer treated with bevacizumab.
Steffensen KD; Madsen CV; Andersen RF; Waldstrøm M; Adimi P; Jakobsen A
Eur J Cancer; 2014 Oct; 50(15):2611-8. PubMed ID: 25087181
[TBL] [Abstract][Full Text] [Related]
18. Ovarian cancer: TRINOVA-1, beyond VEGF inhibition.
Villanueva MT
Nat Rev Clin Oncol; 2014 Aug; 11(8):442. PubMed ID: 25001464
[No Abstract] [Full Text] [Related]
19. Trebananib: an alternative anti-angiogenic strategy.
Gourley C
Lancet Oncol; 2014 Jul; 15(8):776-7. PubMed ID: 24950984
[No Abstract] [Full Text] [Related]
20. Success of bevacizumab trials raises questions for future studies.
Tuma RS
J Natl Cancer Inst; 2005 Jul; 97(13):950-1. PubMed ID: 15998941
[No Abstract] [Full Text] [Related]
[Next] [New Search]
